1. Gut-Busters: IL-17 Ain’t Afraid of No IL-23
Natasha Whibley, Sarah L. Gaffen 
Immunity 
Volume 43, Issue 4, Pages (October 2015)
DOI: /j.immuni
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure 1
Dichotomy between Anti-IL-23 Antibody Treatment and Anti-IL-17 Treatment in Murine Colitis
Blockade of IL-23 ameliorates colitis symptoms in mice, which is associated with reduced expression of inflammatory cytokines and a concomitant increase in the ratio of Treg cells to Th17 cells. Anti-IL-23 therapy is also linked to improvement in epithelial barrier integrity, including increased amounts of Cldn4 mRNA and re-localization of occludin to the tight junction. Conversely, anti-IL-17 or anti-IL-17R antibody treatment triggers elevated amounts of cytokines, decreased Treg cell numbers, epithelial barrier breakdown, and leakiness of lumen contents.
Immunity  , DOI: ( /j.immuni )
Copyright © 2015 Elsevier Inc. Terms and Conditions